Previous studies have shown that human
prostate cancer cells constitutively generate
5-lipoxygenase (5-LOX) metabolites from
arachidonic acid, and inhibition of 5-LOX blocks production of 5-LOX metabolites and triggers apoptosis in
prostate cancer cells. This apoptosis is prevented by exogenous metabolites of 5-LOX, suggesting an essential role of 5-LOX metabolites in the survival of
prostate cancer cells. However, downstream signaling mechanisms which mediate the survival-promoting effects of 5-LOX metabolites in
prostate cancer cells are still unknown. Recently, we reported that MK591, a specific inhibitor of 5-LOX activity, induces apoptosis in
prostate cancer cells without inhibition of Akt, or ERK, two well-characterized regulators of pro-survival mechanisms, suggesting the existence of an Akt and ERK-independent survival mechanism in
prostate cancer cells regulated by 5-LOX. Here, we report that 5-LOX inhibition-induced apoptosis in
prostate cancer cells occurs via rapid inactivation of
protein kinase C-epsilon (PKCε), and that exogenous 5-LOX metabolites prevent both 5-LOX inhibition-induced down-regulation of PKCε and induction of apoptosis. Interestingly, pre-treatment of
prostate cancer cells with
diazoxide (a chemical activator of PKCε), or KAE1-1 (a cell-permeable, octa-
peptide specific activator of PKCε) prevents 5-LOX inhibition-induced apoptosis, which indicates that inhibition of 5-LOX triggers apoptosis in
prostate cancer cells via down-regulation of PKCε. Altogether, these findings suggest that metabolism of
arachidonic acid by 5-LOX activity promotes survival of
prostate cancer cells via signaling through PKCε, a pro-survival
serine/threonine kinase.